19
Views
0
CrossRef citations to date
0
Altmetric
Rapid Communication

The use of a pill containing ethinylestradiol-norgestimate improves female sexuality despite the decrease in circulating androgens: a pilot study

, , , , , & ORCID Icon show all
Pages 160-162 | Received 14 Feb 2024, Accepted 14 Jun 2024, Published online: 28 Jun 2024
 

Abstract

Purpose

To evaluate the initial impact of a combined oral contraceptive (COC) containing norgestimate (NGM) on female sexuality and on circulating androgen levels in users.

Materials and methods

Six months modification in the McCoy Female Sexuality Questionnaire (MFSQ) and testosterone (T) and dehydroepiandrosterone sulphate (DHEAS) serum levels in women starting a monophasic pill containing ethinyl-estradiol (EE) 35 µg and NGM 0.250 mg.

Results

The study was completed by 36 subjects. There was a significant increase in MFSQ during treatment (p < 0.0001) (and its domains with the exclusion of vaginal lubrication domain) with concomitant decreases in T (−4.45%, p < 0.0001) and DHEAS (−19.41%, p < 0.0001) serum levels.

Conclusions

Contraception with EE/NGM was associated with a short term non-deteriorating effect on sexuality despite the evident decrease in androgen levels. Female sexuality during COC use is a complex topic and is not only linked with changes in serum androgen levels.

SHORT CONDENSATION

EE/NGM treatment has a short term non-deteriorating effect on sexuality despite the evident decrease in androgen serum levels.

摘要

目的

评估含诺孕酯(NGM)的复合口服避孕药(COC)对女性性功能和循环雄激素水平的初步影响。

材料和方法

在使用含炔雌醇(EE)35µg和NGM 0.250mg的单相药丸的女性中, 评估麦考伊女性性功能问卷(MFSQ)和睾酮(T)以及硫酸脱氢表雄酮(DHEAS)血清水平用药六个月后的变化。

结果

共有36名受试者完成了研究。治疗期间MFSQ显著增加(p < 0.0001)(及其除阴道润滑领域外的各个领域), 同时T(-4.45%, p < 0.0001)和DHEAS(-19.41%, p < 0.0001)血清水平显著下降。

结论

尽管雄激素水平显著下降, 但EE/NGM避孕药在短期内不会导致性功能变差。COC使用期间的女性性功能是一个复杂的问题, 不仅仅与血清雄激素水平的变化有关。

概述

尽管雄激素血清水平显著下降, 但EE/NGM治疗在短期内不会导致性功能变差。

Disclosure statement

G. Grandi received honoraria for sponsored lectures and participation in advisory boards from Bayer AG, Teva/Theramex, Sandoz Novartis, Exeltis Italy, Merck Sharp & Dohme and Italfarmaco/Effik Italy. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Data availability statement

Data available on request from the authors.

Additional information

Funding

No funds to declare for this study.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.